Prometheus Biosciences Inc
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
(0.0% 1d) (0.0% 1m) (3.1% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-47.11% volume)
Earnings Calendar: 2023-08-09
Market Cap: $ 9,558,822,541
https://www.prometheusbiosciences.com
Sec Filling | Patents | n/a employees
Prometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.
diagnostics gastrointestinal treatment
add to watch list Paper trade email alert is off
Press-releases
Nanomaterials in Personalized Medicine Global Markets Report 2023-2028 with Profiles and Potential of Major Players - BMS, Camurus, Cytimmune Sciences, Eisai, Gilead Sciences, and Ipsen Pharma
Published: 2023-11-16 (Crawled : 00:00) - prnewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
pharma report global potential
Growing Geriatric Population Fuels Ankylosing Spondylitis Market: Management of Pain and Mobility Gains Importance in Aging Demographics
Published: 2023-10-13 (Crawled : 16:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: -1.86%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: -2.78%
H: 0.04%
C: -0.57%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: -1.17%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.55%
H: 0.69%
C: -0.09%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.64%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: -0.59%
H: 0.62%
C: -0.56%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.93%
H: 0.26%
C: -1.25%
management growing
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Published: 2023-04-16 (Crawled : 12:20) - globenewswire.com
MRK | $125.23 -0.11% 0.0% 6M
|
Health Technology
| Email alert
Add to watchlist
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
merck pipeline acquisition immunology
Prometheus Biosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference
Published: 2023-03-09 (Crawled : 14:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -2.72%
H: 0.45%
C: -2.87%
conference
Prometheus Biosciences Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Progress
Published: 2023-02-28 (Crawled : 21:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
financial results
Prometheus Biosciences to Present at the SVB Securities Global Biopharma Conference
Published: 2023-02-09 (Crawled : 22:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -0.92%
H: 0.0%
C: 0.0%
biopharma global conference
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Published: 2023-01-03 (Crawled : 14:20) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
conference
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
Published: 2022-12-09 (Crawled : 01:00) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 8.72%
H: 0.0%
C: 0.0%
offering
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
Published: 2022-12-07 (Crawled : 12:20) - globenewswire.com
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: 181.13%
H: 0.0%
C: 0.0%
pra023 enabling positive phase 2b
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Published: 2022-11-09 (Crawled : 23:00) - biospace.com/
RXDX | $199.92 0.02% 1.9M
|
Professional, Scientific, and T...
|
| O: -0.11%
H: 7.34%
C: 5.68%
financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10